INTERVENTIONAL VASCULAR CORPORATE AND REGIONAL PRESS RELEASES

Please find below a list of our press releases.

14 Dec 2015

BTG announces FDA clearance for LC Bead LUMI, the first commercially available radiopaque embolic bead in the US

Unique LC Bead LUMI™ provides real-time visible confirmation of bead location during embolisation of hypervascular tumours and arteriovenous malformations

27 Sep 2015

BTG announces positive safety and efficacy data in over 500 DC BeadM1™ patients & compelling health economic data for TheraSphere®

BTG plc company (LSE: BTG), announced promising data today for DC BeadM1™, supporting the efficacy and tolerability of doxorubicin-eluting DC BeadM1™ in the treatment of patients diagnosed with liver-confined HCC (hepatocellular carcinoma). The preliminary results of the study, in which patients achieved a median overall survival (OS) of 41 months, were presented during the 2015 CIRSE (Cardiovascular and Interventional Radiological Society of Europe) International Conference in Lisbon, Portugal.

24 Aug 2015

Acute Pulmonary Embolism Trial (SEATTLE II) Published in the JACC: Cardiovascular Interventions

EKOS Corporation, a BTG International group company (BTG plc; LSE: BTG), announced the publication of results of the SEATTLE II trial in the JACC: Cardiovascular Interventions. The study concluded that treatment with ultrasound-facilitated catheter-directed low-dose thrombolysis for acute pulmonary embolism (PE) improves right heart function, reduces blood clot size, and decreases pulmonary hypertension, in patients with intermediate to high risk PE. Importantly, no patient experienced intracranial hemorrhage, a serious adverse experience related to full-dose thrombolysis treatment.

1 Apr 2015

BTG begins sale of DC Bead® and Bead Block® directly to Physicians

BTG plc (LSE: BTG), the specialist healthcare company, today began selling its drug-eluting bead and embolisation products, DC Bead® and Bead Block®, directly to customers in 11 European countries.

13 Oct 2014

BTG to supply DC Bead® and Bead Block® directly to physicians in Europe from 1 April 2015

BTG plc (LSE: BTG), the specialist healthcare company, announces it will begin selling its drug-eluting bead and embolisation products, DC Bead® and Bead Block®, directly to customers in 11 European countries from 1 April 2015.

28 Aug 2014

BTG and SciClone Announce that DC Bead® has been approved by China Food and Drug Administration

BTG plc and its partner SciClone Pharmaceuticals, a China-focused specialty pharmaceutical company, announce that the China Food and Drug Administration has approved the registration of DC Bead® for the embolisation of malignant hypervascularised tumours.

11 Aug 2014

First Varicose Vein Patient Treated with FDA-Approved Varithena® (polidocanol injectable foam) 1%

BTG International Inc. announces that the first varicose vein patient has been treated with Varithena®

11 Jun 2014

EKOS Initiates a Pivotal New Study in Patients with Chronic Deep Vein Thrombosis and Post-Thrombotic Syndrome

EKOS Corporation, a BTG International group company (BTG plc; LSE: BTG), announces the start of patient enrollment for the ACCelerated ThrombolySiS for Post-Thrombotic Syndrome using the EKOS® System (ACCESS PTS) Study.

23 May 2014

EkoSonic® Endovascular System receives FDA Clearance for the Treatment of Pulmonary Embolism in the USA

EKOS Corporation, a BTG International group company announced that the U.S. Food and Drug Administration (FDA) has cleared the EkoSonic® Endovascular System for the ultrasound facilitated, controlled and selective infusion of physician-specified fluids.